Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis

Global Preserving Effective TB Treatment Study (PETTS) Investigatorsa

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

100 Citas (Scopus)

Resumen

Background. Increasing access to drugs for the treatment of multidrug-resistant (MDR) tuberculosis is crucial but could lead to increasing resistance to these same drugs. In 2000, the international Green Light Committee (GLC) initiative began to increase access while attempting to prevent acquired resistance. Methods. To assess the GLC's impact, we followed adults with pulmonary MDR tuberculosis from the start to the end of treatment with monthly sputum cultures, drug susceptibility testing, and genotyping. We compared the frequency and predictors of acquired resistance to second-line drugs (SLDs) in 9 countries that volunteered to participate, 5 countries that met GLC criteria, and 4 countries that did not apply to the GLC. Results. In total, 832 subjects were enrolled. Of those without baseline resistance to specific SLDs, 68 (8.9%) acquired extensively drug-resistant (XDR) tuberculosis, 79 (11.2%) acquired fluoroquinolone (FQ) resistance, and 56 (7.8%) acquired resistance to second-line injectable drugs (SLIs). The relative risk (95% confidence interval [CI]) of acquired resistance was lower at GLC-approved sites: 0.27 (.16-.47) for XDR tuberculosis, 0.28 (.17-.45) for FQ, and 0.15 (.06-.39) to 0.60 (.34-1.05) for 3 different SLIs. The risk increased as the number of potentially effective drugs decreased. Controlling for baseline drug resistance and differences between sites, the odds ratios (95% CIs) were 0.21 (.07-.62) for acquired XDR tuberculosis and 0.23 (.09-.59) for acquired FQ resistance. Conclusions. Treatment of MDR tuberculosis involves substantial risk of acquired resistance to SLDs, increasing as baseline drug resistance increases. The risk was significantly lower in programs documented by the GLC to meet specific standards.

Idioma originalInglés
Páginas (desde-hasta)1049-1063
Número de páginas15
PublicaciónClinical Infectious Diseases
Volumen59
N.º8
DOI
EstadoPublicada - 15 oct 2014

Nota bibliográfica

Publisher Copyright:
© 2014 The Author.

Huella

Profundice en los temas de investigación de 'Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis'. En conjunto forman una huella única.

Citar esto